<DOC>
	<DOCNO>NCT01640119</DOCNO>
	<brief_summary>The investigator want evaluate whether original action base administration alkali ( mainly sodium bicarbonate ) able significantly modify renal death reduce mortality due cardiovascular event . Methods : This proposal Multicentric , prospective , cohort , randomize , open-label control study . The investigator Randomize 728 patient Chronic Kidney Disease ( CKD ) stage 3b ( CKD-3b ) CKD stage 4 : 364 patient include study group call Bicarbonate Group ( Bic ) , level bicarbonate keep &gt; 24 mEq/l ; 364 patient include Usual Treatment Group ( no-Bic ) . Results : The aim Research Protocol demonstrate optimal correction uremic acidosis ( administration sodium bicarbonate alkalinize agent , e.g . sodium citrate ) reduce renal cardiovascular mortality . Conclusions . In conclusion Work Group Conservative Therapy Chronic Renal Insufficiency propose cohort , randomize , control , prospective , multicentric study evaluate effect correction acidosis progression kidney disease consider renal death End-Stage Renal Disease ( ESRD ) patient .</brief_summary>
	<brief_title>Correction Metabolic Acidosis End Stage Renal Disease ( ESRD )</brief_title>
	<detailed_description>Rationale : Chronic Kidney Disease ( CKD ) associate high incidence morbility mortality . In regard , National Health Nutrition Examination Survey ( NANHES ) show 19 % uremic population present metabolic acidosis ( CKD stage 4 ) . This high prevalence low cost correction bicarbonate pave way potential interesting research activity . In fact , Cochrane Collaboration review report evidence correction acidosis sodium bicarbonate pre-End-Stage Renal Disease ) ( ESRD ) patient , concludes randomize control trial ( RCTs ) necessary evaluate benefit harm correct metabolic acidosis pre-ESRD patient . During year , 2009 , another RCT appear scientific literature show administration sodium bicarbonate , consequent correction acidosis , slow progression CKD improve nutritional status ESRD patient stag 4-5 . This study randomize , prospective , open-label , monocentric , conduct 134 patient . It well know acidosis stimulate proteic catabolism , accelerate branched-chain amino acid oxidation reduces synthesis visceral protein . The beneficial effect bicarbonate experimental model rat effect correct acidosis nutritional status also know . Less information available possibility correct acidosis pre-ESRD patient slow renal death improves outcomes also future , dialysis . The cited study Brito Ashurst highlight bicarbonate supplementation ( cause blood value increase 20 22 mmol/L ) slow rate progression CKD better nutritional status patient . Moreover , recently author Menon demonstrate low level serum bicarbonate increase risk outcome , e.g . renal death mortality . Finally , article recently publish Kidney International put evidence pathogenetic factor , e.g . endothelin hyperaldosteronism , cause worsen renal function rat presence metabolic acidosis . In response article , editorial author Sahni , Rosa Batlle D. publish issue Kidney International follow statement : `` There increase evidence alkali therapy retard progression chronic kidney disease ( CKD ) . We summarize recent study discuss mechanism whereby alkali therapy may neutralize acid production associate typical Western diet , generate acid . We emphasize rationale use alkali therapy early course CKD , even absence overt metabolic acidosis , urge pharmaceutical industry develop palatable alkali- contain solution . '' Proposal study For reason explain , Work Group Conservative Therapy Chronic Renal Insufficiency propose cohort , randomize , control , prospective , multicentric study evaluate effect correction acidosis progression kidney disease consider renal death ESRD patient . Objectives : Main objective : 1 . To evaluate whether original action base administration alkali ( mainly sodium bicarbonate ) able significantly modify progression renal disease , renal death , reduce mortality due cardiovascular event . 2 . To verify bicarbonate therapy modify progression renal disease , renal death , reduce mortality due cardiovascular event APKD patient . 3 . To verify bicarbonate therapy modify progression renal disease , renal death , reduce mortality due cardiovascular event dianetic patient . Other objective : To evaluate nutritional parameter improve period study ; To evaluate blood pressure ( absolute value increase antihypertensive drug ) ; To evaluate correction acidosis influence bone turnover ( vascular calcification ) ; To evaluate change calcium phosphorus metabolism . Study design Multicentric , prospective , cohort , randomize control study . Randomize 728 patient CKD-3b CKD-4 : 364 patient include study group call Bicarbonate Group ( Bic ) , level bicarbonate keep &gt; 24 mEq/l ; 364 patient include Usual Treatment Group ( no-Bic ) . Run-in period one visit per month 3 month , follow 36-month study period . The investigated patient must randomize sex , diabetes level renal function ( measure Clearance Creatinine 60 30 ml/min , 30 15 , &lt; 15 pre-dialysis ) requirement Best Practice Treatment ( BPT ) must apply : - For anemia ( Hb 11-12 g/dl ; TSAT &gt; 20 % ) , - For arterial hypertension ( systolic blood pressure ( SBP ) &lt; 130 mmHg ; diastolic blood pressure ( DBP ) &lt; 90 mm g ) , - For hyperlipidemia ( low-density ( LDL ) cholesterol &lt; 100 ) , - For osteodystrophy ( phosphatemia 2.7-4.6 mg/dl ; calcemia 8.4-10.2 mg/dl ; CKD-3 : parathyroid hormone ( PTH ) 35-70 pg/ml ; CKD-4 : PTH 70-110 pg/ml ; 25 ( OH ) vitamin D &gt; 30 nmol/l ) . ( Failure reach BPT target cause exclusion centralize randomization probably reason enrollment patient clinical characteristic treatment follow-up period ) . Randomization centralize patient randomize basis sex , age , diabetes , level renal function ( measure ) . All patient provide nutritional diet counsel consist low protein , phosphorus sodium diet . Duration study : 3 year . Primary endpoint - Doubling Creatinine . Beginning dialysis - All-cause mortality Study Power To determine sample size use EAST software version 3.1 consider following assumption : 1. alfa 0.05 ; 2. power 0.90 ; 3. treatment/untreatment 1 ; 4. lose follow-up 10 % ; 5 . Two-tailed statistical test type I error 5 % . 6 . Statistical power test equal 80 % . Therefore , determine : - Number event require 194 . - Number subject need 728 - Study duration 36 month . Parameters measure every 3-6 month : Bicarbonate level blood albumin level , fetuin-A , C-reactive protein blood level sodium , potassium , bicarbonate , chloride , blood level homocysteine , lipid profile blood level calcium , phosphorus , PTH , alkaline phosphatase , bone turnover marker blood level creatinine , plasma urea , blood count 24h urinary urea excretion , 24h urinary sodium excretion , 24h urinary protein excretion , 24 urinary creatinine excretion bioelectrical impedance assessment ( BIA ) , body weight , blood pressure , Lateral abdominal X-ray vascular calcification . Use anti-hypertensive drug diuretic . Administration bicarbonates : The molecular weight sodium bicarbonate 84.01 . Each gram substance therefore contain 11.9 mmol , initially much 3-4 gram administer , subsequently adjust accord blood level bicarbonate . Evaluations make bimonthly basis order adjust administration bicarbonate accord blood level bicarbonate ( target value &gt; 24 e &lt; 28 mEq/L ) . Bicarbonate administration suspend blood bicarbonate level &gt; 28 mEq/L . For ethical reason , partial correction acidosis allow ( 22 mEq/L ) blood bicarbonate level low 18 mEq/L . The aim study demonstrate optimal correction uremic acidosis ( administration sodium bicarbonate alkalinize agent , e.g . sodium citrate ) reduce renal cardiovascular mortality . Prerequisites study : ) expose patient low risk unfavourable event , c ) patient ask little constant effort modification life style , ) cost low family institution patient treat . No specific equipment competence require , study easily perform Nephrology Division . -- -- -- -- -- -- -- -- -- -- -- -- - Ethical aspect The physician describe study detail read information regard study patient he/she opportunity ask clarification . Thereafter , patient provide Informed Consent , he/she sign read throughout ( see attachment ) . Patient 's data record , process stored complete accordance data protection law , order safeguard safety privacy data ; include publication and/or present conference , data undergo statical process keep anonymous . Statistics Methods descriptive distribution statistic together parametric non-parametric test apply . Linear correlation Spearman test use analyse relationship two variable consider simultaneously ; relationship among variable analyse multiple regression ( linear logistic ) .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Acidosis</mesh_term>
	<criteria>End stage renal disease Neoplastic diseases Autoimmune diseases Decompensation class IIIIV Uncontrollable hypertension Amputation limbs Previous ictus cerebri Neobladder , ureterosigmoidostomy Sever acidosis bicarbonate &lt; 18 mEq/l Use calcium carbonate ( relative exclusion factor : patient used take drug suspend begin 3month runin period include study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>metabolic acidosis</keyword>
	<keyword>renal death</keyword>
</DOC>